Charles Schwab Investment Management Inc Avidity Biosciences, Inc. Transaction History
Charles Schwab Investment Management Inc
- $519 Billion
- Q2 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 793,117 shares of RNA stock, worth $35.4 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
793,117
Previous 548,435
44.61%
Holding current value
$35.4 Million
Previous $14 Million
131.48%
% of portfolio
0.01%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding RNA
# of Institutions
206Shares Held
95.5MCall Options Held
171KPut Options Held
196K-
Price T Rowe Associates Inc Baltimore, MD10.9MShares$487 Million0.05% of portfolio
-
Rtw Investments, LP New York, NY8.81MShares$393 Million6.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$385 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.51MShares$290 Million3.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.94MShares$265 Million0.0% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $2.33B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...